₹4,631.55 on the BSE. On the NSE, it closed 4.17 per cent higher at ₹4,442.35.On August 11, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world's first registered vaccine against COVID-19 based on the human adenoviral vectors platform."Dr Reddys’ would carry out Phase 3 trials in India and, once approved, we understand opportunity can be large and result in one time revenue gain (if trials successful); albeit, there is no certainty on trial outcome and more importantly pricing would be keenly watched by govt.